Clinical trial researching medication therapy for IDH2-mutated nasal cavity or skull base tumors

Patient with doctor

Image credit: Canva

Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body. These cancers may have mutations in a gene called IDH2. A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching targeted medication therapy for patients with IDH2-mutated tumors in the nasal cavity or skull base area.

The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.

For more information, please contact the NCI Medical Oncology Referral Office at or (888) 624-1937 identifier: NCT06176989

NCI Protocol ID: IRB001552

Official Title: Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland. 

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Posted on Wed, 03/27/2024